title: Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist.
abstract: The role of complement components in traumatic brain injury is poorly understood. Here we show that secondary damage after acute cryoinjury is significantly reduced in C3-/- or C5-/- mice or in mice treated with C5a receptor antagonist peptides. Injury sizes and neutrophil extravasation were compared. While neutrophil density increased following traumatic brain injury in wild type (C57BL/6) mice, C3-deficient mice demonstrated lower neutrophil extravasation and injury sizes in the brain. RNase protection assay indicated that C3 contributes to the induction of brain inflammatory mediators, MIF, RANTES (CCL5) and MCP-1 (CCL2). Intracranial C3 injection induced neutrophil extravasation in injured brains of C3-/- mice suggesting locally produced C3 is important in brain inflammation. We show that neutrophil extravasation is significantly reduced in both C5-/- mice and C5a receptor antagonist treated cryoinjured mice suggesting that one of the possible mechanisms of C3 effect on neutrophil extravasation is mediated via downstream complement activation products such as C5a. Our data indicates that complement inhibitors may ameliorate traumatic brain injury.
authors.affiliation: Department of Pathology, University of Wisconsin-Madison, 1300 University Ave, Madison, WI 53706, USA.
authors.forename: Diane L
authors.initials: DL
authors.lastname: Sewell
authors.forename: Brendon
authors.initials: B
authors.lastname: Nacewicz
authors.forename: Frances
authors.initials: F
authors.lastname: Liu
authors.forename: Sinarack
authors.initials: S
authors.lastname: Macvilay
authors.forename: Anna
authors.initials: A
authors.lastname: Erdei
authors.forename: John D
authors.initials: JD
authors.lastname: Lambris
authors.forename: Matyas
authors.initials: M
authors.lastname: Sandor
authors.forename: Zsuzsa
authors.initials: Z
authors.lastname: Fabry
mesh_terms: D000818:Animals; D001930:Brain Injuries / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D018932:Chemokine CCL2 / Q000235:genetics; D018946:Chemokine CCL5 / Q000235:genetics; D002634:Chemotaxis, Leukocyte / Q000187:drug effects* / Q000276:immunology; D003080:Cold Temperature / Q000009:adverse effects; D003176:Complement C3 / Q000235:genetics / Q000502:physiology*; D003182:Complement C5 / Q000235:genetics / Q000502:physiology*; D004195:Disease Models, Animal; D018836:Inflammation Mediators / Q000378:metabolism; D019746:Intramolecular Oxidoreductases; D008263:Macrophage Migration-Inhibitory Factors / Q000235:genetics; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009504:Neutrophils / Q000187:drug effects* / Q000276:immunology / Q000473:pathology; D010455:Peptides / Q000276:immunology / Q000494:pharmacology; D012333:RNA, Messenger / Q000378:metabolism; D044087:Receptor, Anaphylatoxin C5a / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D018932:Chemokine CCL2; D018946:Chemokine CCL5; D003176:Complement C3; D003182:Complement C5; D018836:Inflammation Mediators; D008263:Macrophage Migration-Inhibitory Factors; D010455:Peptides; D012333:RNA, Messenger; D044087:Receptor, Anaphylatoxin C5a; D019746:Intramolecular Oxidoreductases; C076231:Mif protein, mouse